ICCC - Immucell Corp.
IEX Last Trade
3.74
-0.070 -1.872%
Share volume: 39,701
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.81
-0.07
-1.84%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-21 | 2023-03-29 | 2023-05-11 | 2023-08-10 | 2023-11-13 | 2024-04-01 | 2024-05-14 | |
| Assets | |||||||||
| Total Assets | 45.984 M | 46.402 M | 44.861 M | 43.123 M | 44.007 M | 44.545 M | 43.808 M | 43.051 M | |
| Current Assets | 17.328 M | 16.433 M | 13.995 M | 12.248 M | 10.946 M | 11.962 M | 11.470 M | 11.348 M | |
| Inventories | 4.603 M | 5.318 M | 6.039 M | 6.328 M | 7.536 M | 7.386 M | 7.812 M | 7.150 M | |
| Other Current Assets | 244.262 K | 552.431 K | 363.877 K | 681.831 K | 433.237 K | 577.477 K | 454.152 K | 562.573 K | |
| Short Term Investments | 244.262 K | 552.431 K | 363.877 K | 681.831 K | 433.237 K | 577.477 K | 454.152 K | 562.573 K | |
| Total Receivables | 1.438 M | 1.735 M | 1.801 M | 2.142 M | 1.522 M | 2.010 M | 2.225 M | 2.675 M | |
| Current Cash | 11.043 M | 8.828 M | 5.792 M | 3.096 M | 1.454 M | 1.989 M | 978.741 K | 960.347 K | |
| Total Non-current Assets | 28.655 M | 29.968 M | 30.866 M | 30.875 M | 33.062 M | 32.583 M | 32.338 M | 31.703 M | |
| Property Plant Equipment | 27.418 M | 27.570 M | 28.442 M | 28.461 M | 28.551 M | 28.158 M | 27.576 M | 26.982 M | |
| Other Assets | 23.783 K | 24.567 K | 76.628 K | 87.781 K | 82.459 K | 70.041 K | 57.655 K | 46.248 K | |
| Intangible Assets | 66.864 K | 62.088 K | 57.312 K | 52.536 K | 47.760 K | 42.984 K | 38.208 K | 33.432 K | |
| Goodwill | 95.557 K | 95.557 K | 95.557 K | 95.557 K | 95.557 K | 95.557 K | 95.557 K | 95.557 K | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 45.984 M | 46.402 M | 44.861 M | 43.123 M | 44.007 M | 44.545 M | 43.808 M | 43.051 M | |
| Total liabilities | 13.209 M | 14.419 M | 14.481 M | 14.962 M | 17.150 M | 18.532 M | 18.815 M | 18.415 M | |
| Total current liabilities | 2.509 M | 2.715 M | 3.072 M | 3.838 M | 4.193 M | 3.328 M | 4.197 M | 4.184 M | |
| Accounts Payable | 643.875 K | 759.335 K | 789.997 K | 794.853 K | 918.399 K | 779.846 K | 887.733 K | 737.333 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 966.996 K | 998.160 K | 1.039 M | 2.064 M | 2.090 M | 1.411 M | 1.429 M | 1.444 M | |
| Long term debt | 9.731 M | 9.479 M | 9.191 M | 8.917 M | 8.641 M | 10.905 M | 10.540 M | 10.169 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 32.775 M | 31.983 M | 30.380 M | 28.161 M | 26.857 M | 26.013 M | 24.993 M | 24.636 M | |
| Common stock | 7.745 M | 7.747 M | 7.747 M | 7.747 M | 7.747 M | 7.747 M | 7.750 M | 7.751 M | |
| Retained earnings | -3.687 M | -4.565 M | -6.232 M | -8.548 M | -9.927 M | -10.867 M | -12.007 M | -12.445 M |